Trial halted early: testing a scarring drug for rare lung disease
NCT ID NCT05335278
Summary
This study aimed to see if adding the drug nintedanib to standard immune-suppressing medications was safe and tolerable for adults with myositis-related interstitial lung disease (MA-ILD), a condition where muscle inflammation causes progressive lung scarring. The goal was to slow down lung damage in patients already on stable immune therapy. The trial was terminated early after enrolling only 11 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Institute McGill University Health Center
Montreal, Quebec, H4A3J1, Canada
Conditions
Explore the condition pages connected to this study.